Autism and Communication |
|
|
Clinical Trial: Drug Treatment for Autism
This study is currently recruiting patients.
|
Purpose
The purpose of this study is to examine the safety and effectiveness of donepezil HCl (Aricept) in children and adolescents with Autism Spectrum Disorder (ASD).
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Autistic Disorder | Drug: Donepezil HCl | Phase I |
MedlinePlus related topics: Autism
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Donepezil HCl: Treating Cognitive Deficits in Autism
Expected Total Enrollment: 40
Study start: October 2002; Expected completion: August 2005
Children with autism spectrum disorder (ASD) often have impaired communication, problems with social interaction, and repetitive and stereotyped patterns of behavior. While most research has attempted to treat the behavioral deficits commonly associated with ASD, few studies have attempted to improve the core features of this disorder. A recent study found that donepezil HCl helped to improve speech production, attention span, and ability to express emotions in a group of children with autism. This study will provide an opportunity to conduct further testing of the effects of donepezil HCl on the cognitive deficits presumed to underlie the core features of ASD.
This study begins at Week 1 with a baseline assessment. Participants are then randomly assigned to either donepezil HCl or placebo. Participants will start with either a 5mg/day dose of donezepil HCl or placebo followed by a cognitive assessment after 4 weeks on this dose. Participants will then have their dose increased to 10mg/day. Another cognitive assessment will be given after 4 weeks on this dose.
Eligibility
Ages Eligible for Study: 8 Years - 17 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Autism Spectrum Disorder (ASD)
- Asperger's Disorder
- IQ of 75 or above
- Baseline assessment tests within the acceptable range
Exclusion Criteria:
- Bipolar disorder, schizophrenia, schizoaffective disorder, or psychotic disorder
- Seizure disorder requiring the use of anticonvulsant medications
- Congenital rubella, cytomegalovirus, or tuberous sclerosis
- Certain medications prescribed for management of behavior (please contact the investigator for a complete list)
- Medications/preparations that are known to interact with donepezil HCl
- Significant medical illness, endocrinopathies, cardiovascular disease, or severe chronic malnutrition
- Pregnancy or sexually active females not using a reliable method of contraception
Location and Contact Information
Sarah McAuliffe-Bellin, M.Ed. 412-235-5447 mcauliffebellnsj@msx.upmc.edu
Pennsylvania
Western Psychiatric Institute & Clinic, Pittsburgh, Pennsylvania, 15213, United States; Recruiting
Sarah McAuliffe-Bellin, M.Ed. 412-235-5447 mcauliffebellinsj@msx.upmc.edu
Benjamin L Handen, Ph.D., Principal Investigator
Antonio Y Hardan, M.D., Sub-Investigator
Cynthia R Johnson, Ph.D., Sub-Investigator
Benjamin L. Handen, Ph.D., Principal Investigator, University of Pittsburgh, School of Medicine, Department of Psychiatry
More Information
Record last reviewed: December 2004
Last Updated: December 6, 2004
Record first received: October 11, 2002
ClinicalTrials.gov Identifier: NCT00047697
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Not Signed In -


